Mednet Logo
SpecialtiesRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

How do you manage dry eye syndrome due to lacrimal or meiobian gland dysfunction after external beam radiotherapy?

5
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Yale Cancer Center At Smilow Cancer Hospital

I have also found autologous serum (AS) or platelet-rich plasma (PRP) eye drops/tears to be extremely useful (provided by an ophthalmologist). Dry eye can also be exacerbated by graft vs. host disease, which I have anecdotally seen worsened within radiation fields and is characterized by a lasting m...

Do you offer RT both to the prostate and synchronous oligometastases in de novo oligometastatic prostate cancer?

12
6 Answers

Mednet Member
Mednet Member
Radiation Oncology · UC San Diego

We do not yet have good evidence to tell us whether or when we should offer metastasis-directed therapy (MDT) for de novo oligometastatic prostate cancer. ORIOLE (like STOMP) was conducted in the recurrent setting. Those trials showed that MDT could delay progression and possibly allow a delay in th...

Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?

12
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

This will be a long response to try to provide transparency to these tests from what I know as a researcher and clinician. I also clinically see this situation frequently. We have made incredible progress in developing biomarkers in prostate cancer, but it is important to know that no single test is...

Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?

13
6 Answers

Mednet Member
Mednet Member
Neurology · Cedars-Sinai Medical Center

Interesting question. Not being an endocrinologist, I don't have the expertise to advise but the reference below makes the statement that even short-term steroids can be an issue. I suspect that if you have to stop abruptly from 60 mg daily for 2 weeks, it would probably be fine in most instances bu...

How are you modifying your current sarcoma-directed therapy in the setting of the COVID-19 pandemic?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Fox Chase Cancer Center

Here are the guidelines at Fox Chase Cancer Center by Margaret von Mehren MD, @Dr. First Last , Jeffrey Farma MD, Sanjay Reddy MD, John Abraham, MD, and Stephanie Greco, MD I. Management of STS during COVID-19 Pandemic: During the current pandemic, care will need to be changed to allow for hospitals...

How do you approach rising PSA following radical prostatectomy and early salvage radiation therapy?

7
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

There are several factors that I will take into consideration, including the patient's overall health, the interval from treatment to relapse, the PSA doubling time (rather than a PSA threshold), whether or not they're castrate resistant and whether or not they now have overt metastatic disease. Pat...

What is the best treatment for a medically inoperable endometrial adenocarcinoma of the uterus FIGO 1, grade 1, type 1?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

I would get a pelvic MRI to assess tumor size and myometrial involvement. If small volume (2 cm or smaller) with superficial invasion then use brachy alone, otherwise EBRT plus brachy. The type of brachy is based on uterine width: If the width is less than 5 cm: single tandem and cylinder. Otherwise...

How do you approach adjuvant therapy for resected lung adenocarcinoma that was found unexpectedly postop to be N2?

6
10 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Preliminary results of the phase 3 randomized LungART trial (NCT00410683) were recently presented at a virtual ESMO conference. 501 patients with pathologically confirmed N2 NSCLC s/p complete resection were randomized to postoperative RT (54 Gy) or observation. Almost all patients received chemothe...

What are your top takeaways in Breast Cancer from ESMO 2025?

3
7 Answers

Mednet Member
Mednet Member
Medical Oncology · Emory University Winship Cancer Institute Midtown

ASCENT-03: At ASCO, the results of ASCENT-04 already showed an improvement of PFS (11.2 months vs. 7.8 months) in first-line setting for PD-L1 positive advanced triple negative breast cancer patients treated with sacituzumab plus pembrolizumab compared to chemotherapy plus pembrolizumab. The ASCE...

How do you manage significant gas in patients undergoing pelvic radiotherapy?

2
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · Michigan Healthcare Professionals, PC

This is tough, especially once the simulation is completed, the patient comes in for treatments and now you see very different anatomy. The one thing that I have changed in practice - and I'm aware this is not always possible at higher volume centers - is to have the simulation at about the same tim...